Saturday, October 23, 2021

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021 Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment $355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious…

Government tackling corruption head on

Public beliefs about a perceived increase in corrupt activities may be as a result of increased action against corrupt officials and reports thereof.This is according to a statement from the Presidency following the release of an Afrobarometer corrupti...